Mono Pharmacare Ltd. stands out as a deep value pick in the trading sector due to its low valuation metrics despite its moderate profitability. While it has no current revenue growth and a relatively high debt-equity ratio, it maintains a solid ROE compared to peers. This suggests potential for recovery or undervaluation, positioning it as an attractive option for value investors.

• • Mono Pharmacare Ltd. has a PE ratio of 0.00, indicating potential undervaluation.
• • It demonstrates good ROE at 11.8574, despite other weak financial metrics.
• • The company shows no revenue growth, but could be a turnaround candidate.